1. Cell Biology
  2. Immunology and Inflammation

Robust T cell activation requires an eIF3-driven burst in T cell receptor translation

  1. Dasmanthie DeSilva
  2. Lucas Ferguson
  3. Grant H Chin
  4. Benjamin E Smith
  5. Ryan A Apathy
  6. Theodore L Roth
  7. Franziska Blaeschke
  8. Marek Kudla
  9. Alexander Marson
  10. Nicholas T Ingolia
  11. Jamie HD Cate  Is a corresponding author
  1. University of California, Berkeley, United States
  2. University of California, San Francisco, United States
  3. Gladstone-UCSF Institute of Genomic Immunology, United States
https://doi.org/10.7554/eLife.74272
Share this article
Cite this article
  1. Dasmanthie DeSilva
  2. Lucas Ferguson
  3. Grant H Chin
  4. Benjamin E Smith
  5. Ryan A Apathy
  6. Theodore L Roth
  7. Franziska Blaeschke
  8. Marek Kudla
  9. Alexander Marson
  10. Nicholas T Ingolia
  11. Jamie HD Cate
(2021)
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation
eLife 10:e74272.
https://doi.org/10.7554/eLife.74272
  2. Download BibTeX
  3. Download .RIS

Abstract

Activation of T cells requires a rapid surge in cellular protein synthesis. However, the role of translation initiation in the early induction of specific genes remains unclear. Here we show human translation initiation factor eIF3 interacts with select immune system related mRNAs including those encoding the T cell receptor (TCR) subunits TCRA and TCRB. Binding of eIF3 to the TCRA and TCRB mRNA 3'-untranslated regions (3'-UTRs) depends on CD28 coreceptor signaling and regulates a burst in TCR translation required for robust T cell activation. Use of the TCRA or TCRB 3'-UTRs to control expression of an anti-CD19 chimeric antigen receptor (CAR) improves the ability of CAR-T cells to kill tumor cells in vitro. These results identify a new mechanism of eIF3-mediated translation control that can aid T cell engineering for immunotherapy applications.

Data availability

Sequencing data has been deposited in GEO (GSE191306).Code used to analyze the microscopy images is available on github at https://github.com/Llamero/TCR_colocalization_analysis-macro

The following data sets were generated

Article and author information

Author details

  1. Dasmanthie DeSilva

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    Dasmanthie DeSilva, A provisional patent application has been filed on some of the work presented herein..

  2. Lucas Ferguson

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.

  3. Grant H Chin

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.

  4. Benjamin E Smith

    School of Optometry, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.

  5. Ryan A Apathy

    Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  6. Theodore L Roth

    Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Theodore L Roth, is a co-founder of Arsenal Therapeutics..

  7. Franziska Blaeschke

    Gladstone-UCSF Institute of Genomic Immunology, San Francisco, United States
    Competing interests
    No competing interests declared.

  8. Marek Kudla

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.

  9. Alexander Marson

    Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Alexander Marson, is a compensated co-founder, member of the boards of directors, and a member of the scientific advisory boards of Spotlight Therapeutics and Arsenal Biosciences. Was a compensated member of the scientific advisory board at PACT Pharma and was a compensated advisor to Juno Therapeutics. Owns stock in Arsenal Biosciences, Spotlight Therapeutics, PACT Pharma and Merck. A.M. has received fees from Vertex, Merck, Amgen, Trizell, Genentech, AlphaSights, Rupert Case Management and Bernstein. Is an investor in and informal advisor to Offline Ventures. The Marson lab has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead, and Anthem..

  10. Nicholas T Ingolia

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3395-1545

  11. Jamie HD Cate

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    For correspondence
    j-h-doudna-cate@berkeley.edu
    Competing interests
    Jamie HD Cate, A provisional patent application has been filed on some of the work presented herein..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5965-7902

Funding

National Institutes of Health (R01-GM065050)

  • Dasmanthie DeSilva
  • Grant H Chin
  • Jamie HD Cate

Cancer Research Institute (N/A)

  • Alexander Marson

Chan Zuckerberg Initiative (N/A)

  • Ryan A Apathy
  • Theodore L Roth
  • Alexander Marson

Innovative Genomics Institute (N/A)

  • Ryan A Apathy
  • Theodore L Roth
  • Alexander Marson

Parker Institute for Cancer Immunotherapy (N/A)

  • Alexander Marson

Tang Prize for Biopharmaceutical Science (N/A)

  • Jamie HD Cate

Damon Runyon Cancer Research Foundation (DRR#37-15)

  • Nicholas T Ingolia

National Institutes of Health (DP2 CA195768)

  • Lucas Ferguson
  • Marek Kudla
  • Nicholas T Ingolia

National Institutes of Health (P30EY003176)

  • Benjamin E Smith

National Institutes of Health (S10 OD018174)

  • Dasmanthie DeSilva

Care-for-Rare Foundation (N/A)

  • Franziska Blaeschke

German Research Foundation (N/A)

  • Franziska Blaeschke

Burroughs Wellcome Fund (N/A)

  • Alexander Marson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, DeSilva et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,284
    views
  • 585
    downloads
  • 22
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Dasmanthie DeSilva
  2. Lucas Ferguson
  3. Grant H Chin
  4. Benjamin E Smith
  5. Ryan A Apathy
  6. Theodore L Roth
  7. Franziska Blaeschke
  8. Marek Kudla
  9. Alexander Marson
  10. Nicholas T Ingolia
  11. Jamie HD Cate
(2021)
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation
eLife 10:e74272.
https://doi.org/10.7554/eLife.74272

Share this article

https://doi.org/10.7554/eLife.74272

Categories and tags

Research organism

Further reading

    1. Cell Biology

    A ‘torn bag mechanism’ of small extracellular vesicle release via limiting membrane rupture of en bloc released amphisomes (amphiectosomes)

    Tamás Visnovitz, Dorina Lenzinger ... Edit I Buzas
    Short Report

    Recent studies showed an unexpected complexity of extracellular vesicle (EV) biogenesis pathways. We previously found evidence that human colorectal cancer cells in vivo release large multivesicular body-like structures en bloc. Here, we tested whether this large EV type is unique to colorectal cancer cells. We found that all cell types we studied (including different cell lines and cells in their original tissue environment) released multivesicular large EVs (MV-lEVs). We also demonstrated that upon spontaneous rupture of the limiting membrane of the MV-lEVs, their intraluminal vesicles (ILVs) escaped to the extracellular environment by a ‘torn bag mechanism’. We proved that the MV-lEVs were released by ectocytosis of amphisomes (hence, we termed them amphiectosomes). Both ILVs of amphiectosomes and small EVs separated from conditioned media were either exclusively CD63 or LC3B positive. According to our model, upon fusion of multivesicular bodies with autophagosomes, fragments of the autophagosomal inner membrane curl up to form LC3B positive ILVs of amphisomes, while CD63 positive small EVs are of multivesicular body origin. Our data suggest a novel common release mechanism for small EVs, distinct from the exocytosis of multivesicular bodies or amphisomes, as well as the small ectosome release pathway.

    1. Cell Biology

    Artesunate, EDTA, and colistin work synergistically against MCR-negative and -positive colistin-resistant Salmonella

    Yajun Zhai, Peiyi Liu ... Gongzheng Hu
    Research Article

    Discovering new strategies to combat the multidrug-resistant bacteria constitutes a major medical challenge of our time. Previously, artesunate (AS) has been reported to exert antibacterial enhancement activity in combination with β-lactam antibiotics via inhibition of the efflux pump AcrB. However, combination of AS and colistin (COL) revealed a weak synergistic effect against a limited number of strains, and few studies have further explored its possible mechanism of synergistic action. In this article, we found that AS and EDTA could strikingly enhance the antibacterial effects of COL against mcr-1- and mcr-1+ Salmonella strains either in vitro or in vivo, when used in triple combination. The excellent bacteriostatic effect was primarily related to the increased cell membrane damage, accumulation of toxic compounds and inhibition of MCR-1. The potential binding sites of AS to MCR-1 (THR283, SER284, and TYR287) were critical for its inhibition of MCR-1 activity. Additionally, we also demonstrated that the CheA of chemosensory system and virulence-related protein SpvD were critical for the bacteriostatic synergistic effects of the triple combination. Selectively targeting CheA, SpvD, or MCR using the natural compound AS could be further investigated as an attractive strategy for the treatment of Salmonella infection. Collectively, our work opens new avenues toward the potentiation of COL and reveals an alternative drug combination strategy to overcome COL-resistant bacterial infections.

    1. Cell Biology
    2. Genetics and Genomics

    The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2

    Adam D Longhurst, Kyle Wang ... David P Toczyski
    Tools and Resources

    Progression through the G1 phase of the cell cycle is the most highly regulated step in cellular division. We employed a chemogenetic approach to discover novel cellular networks that regulate cell cycle progression. This approach uncovered functional clusters of genes that altered sensitivity of cells to inhibitors of the G1/S transition. Mutation of components of the Polycomb Repressor Complex 2 rescued proliferation inhibition caused by the CDK4/6 inhibitor palbociclib, but not to inhibitors of S phase or mitosis. In addition to its core catalytic subunits, mutation of the PRC2.1 accessory protein MTF2, but not the PRC2.2 protein JARID2, rendered cells resistant to palbociclib treatment. We found that PRC2.1 (MTF2), but not PRC2.2 (JARID2), was critical for promoting H3K27me3 deposition at CpG islands genome-wide and in promoters. This included the CpG islands in the promoter of the CDK4/6 cyclins CCND1 and CCND2, and loss of MTF2 lead to upregulation of both CCND1 and CCND2. Our results demonstrate a role for PRC2.1, but not PRC2.2, in antagonizing G1 progression in a diversity of cell linages, including chronic myeloid leukemia (CML), breast cancer, and immortalized cell lines.